The PASTEL catalogue of stellar parameters

The PASTEL catalogue is an update of the [Fe/H] catalogue, published in 1997 and 2001. It is a bibliographical compilation of stellar atmospheric parameters providing (Teff,logg,[Fe/H]) determinations obtained from the analysis of high resolution, high signal-to-noise spectra, carried out with model atmospheres. PASTEL also provides determinations of the one parameter Teff based on various methods. It is aimed in the future to provide also homogenized atmospheric parameters and elemental abundances, radial and rotational velocities. A web interface has been created to query the catalogue on elaborated criteria. PASTEL is also distributed through the CDS database and VizieR. To make it as complete as possible, the main journals have been surveyed, as well as the CDS database, to find relevant publications. The catalogue is regularly updated with new determinations found in the literature. As of Febuary 2010, PASTEL includes 30151 determinations of either Teff or (Teff,logg,[Fe/H]) for 16649 different stars corresponding to 865 bibliographical references. Nearly 6000 stars have a determination of the three parameters (Teff,logg,[Fe/H]) with a high quality spectroscopic metallicity.Comment: 5 pages, accepted for publication in A&A. The PASTEL catalogue can be queried at http://pastel.obs.u-bordeaux1.fr/ or http://vizier.u-strasbg.fr/viz-bin/VizieR?-source=B/paste

Observation of Top Quark Production in Proton-Nucleus Collisions

Peer reviewe

The PASTEL catalogue (Soubiran+, 2010)

VizieR On-line Data Catalog: B/pastel. Originally published in: 2010A&A...515A.111SPASTEL is a bibliographical catalogue compiling determinations of stellar atmospheric parameters. It provides (Teff, logg, [Fe/H]) determinations obtained from detailed analyses of high resolution, high signal to noise spectra, carried out with the help of model atmospheres. It also provides effective temperatures Teff from various methods. PASTEL is regularly updated. The catalogue supersedes the two previous versions of the [Fe/H] catalogue (Cayrel de Strobel et al., 1997 [Cat. III/200], 2001 [Cat. III/221]). (1 data file)

Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

International audienc

How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study

International audienceBACKGROUND and AIMS: Optimal management of patients with inflammatory bowel disease (IBD) after anti-TNF discontinuation due to severe induced skin lesions is unclear. Our study aimed to describe dermatological and IBD evolution after anti-TNF discontinuation for this side effect. METHODS: We conducted a multicenter retrospective study including consecutive IBD patients who discontinued anti-TNF due to severe induced skin lesions. Objectives were to determine factors associated with dermatological remission (complete disappearance of skin lesions) and with IBD relapse in patients with inactive disease at inclusion, notably the impact of an early switch to another biological agent within three months of anti-TNF discontinuation. RESULTS: Among the 181 patients (134 women, 160 Crohn’s disease) included in the 13 participating centers, dermatological remission occurred in 110 (62%) patients with a median (interquartile range) interval of 8.0 (6.8-11.0) months. Scalp location was independently associated with less remission of skin lesions [hazard ratio (HR) =0.64 (95%CI 0.43- 0.94), p=0.02] while early switch was independently associated with a higher probability of remission of skin lesions [HR=1.64 (95%CI 1.1-2.5), p=0.02]. Among the 148 patients with inactive IBD at inclusion, disease relapse occurred in 75 (51%) patients with a median (IQR) interval of 26.0 (23.0-39.1) months. Survival rates without IBD relapse at 1 year were 85.8% (95%CI 77.5-94.9) in the early switch group and 59.3% (95%CI 48.9-71.9) in the other group (p<0.01). CONCLUSIONS: Early switch to a new biological is associated with higher probability of healing of anti-TNF-induced skin lesions and significantly reduces risk of IBD relapse

Recommandations de pratique pour le diagnostic et la prise en charge de la rectocolite hémorragique

National audienceBackground: Updating French clinical guidelines for diagnostic and management of ulcerative colitis is needed due to the emergence of new treatments and treatment goals. Methods: On behalf of the Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), French clinical guidelines were updated through a validated process of adaptation of clinical guidelines from international Gastroenterology societies and French consensus meetings. Results: French clinical guidelines for the diagnostic and management of ulcerative colitis were drafted by 16 GETAID members and reviewed by 6 members of the GETAID, the Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) and the Club de Réflexion des Cabinets et Groupes d'Hépato-Gastroentérologie (CREGG), graded according to the level of Evidence and the level of agreement by 68 experts from the latter three societies. The present guidelines focused on classification, diagnosis, histopathology, extra-intestinal manifestations, dysplasia and colorectal cancer, pouchitis, medical management of active disease and maintenance therapy.. Conclusion: This paper provides updated and useful guidelines for French gastroenterologists to diagnose and treat patients with ulcerative colitis. © John Libbey Eurotext, 2022

P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study

International audienceBackground Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD) unrelated to the disease or its treatment (Poullenot F et al. JCC 2022). The main aim of our study was to assess the risk of incident cancer according to the IBD treatment given in patients with prior breast cancer. Methods Consecutive IBD patients with prior breast cancer diagnosis were included in a multicenter retrospective cohort from 25 tertiary centres. Inclusion date corresponded to the diagnosis of index cancer. Follow up was calculated from the first administration of immunomodulator after cancer diagnosis (or cancer diagnosis date in absence of treatment) to the occurrence of incident cancer, corresponding to recurrence of breast cancer or de novo cancer, or to the last follow-up visit. Patients were categorized according to the use or not of immunomodulator after cancer diagnosis: thiopurines, methotrexate, anti-TNF, vedolizumab, ustekinumab. Crude incidence rates were compared between patients receiving at least one immunomodulator and those without immunomodulator before and after matching on age, lymph node, and metastasis extension and tumor’s grade, using a propensity-score analysis with a 1:1 ratio. Results Among the 151 identified patients, 80 patients with full available data were analyzed: 76 (95%) women; mean age at index cancer diagnosis: 51.5 years [standard deviation (SD): 11.5 years]; 44 (55%) with Crohn’s disease, 35 (44 %) ulcerative colitis and 1 (1 %) indeterminate colitis; median IBD duration at inclusion was 13 years [interquartile range (IQR) 6-21]. After a median follow up of 84 months [IQR 49-154], 16 (20%) incident cancers were observed: 12 (15%) recurrences and 4 (5%) cancer de novo. Three (4%) patients died from cancer related cause during the follow up. 39 (49%) patients received no immunomodulator and, 11 (14%) were treated with thiopurines, 6 (7.5%) with methotrexate, 18 (22.5%) with anti-TNF, 5 (6%) with vedolizumab and one (1%) with ustekinumab. Those treatments were initiated with a median interval of 24 months [IQR 7-48] after cancer diagnosis. Crude incidence rate per 1000 person-years were 47.97 for patients not exposed to any immunomodulator and 12.61 for the others (p=0.0248). After matching, adjusted crude incidence rates per 1000 person-years were 50 and 27.27, respectively (p=0.3798). Rates of survival without incident cancer were not different between the two groups after matching on age, lymph node, metastasis extension, and tumor’s grade (p=0.17) (Figure 1). Conclusion In the present multicenter retrospective cohort, incident cancer risk among patient with IBD and prior breast cancer was not increased in patients subsequently exposed to immunomodulators

DOP89 Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study

International audienceBackground While the effect of anti-TNFs on postoperative outcomes in patients with Crohn's disease (CD) has been widely studied, the impact of vedolizumab and ustekinumab on the risk of postoperative complications remains poorly known. Methods All consecutive patients who underwent intestinal resection for CD between July 2014 and April 2022 within 22 French centers were included in a retrospective cohort. The risk of early post-operative complications (≤30days) in patients exposed to biologics was compared to patients not exposed by logistic regression and propensity score-matched analysis adjusted for age, previous intestinal resection, corticosteroids or immunosuppressants exposure, disease activity, presence of abscess, urgent surgery and initial stoma (preoperative contra-indication to anastomosis). Results Among the 1201 patients included, respectively 491 (41%), 76 (6.3%) and 57 (4.7%) were exposed to anti-TNFs, ustekinumab, or vedolizumab within six months before surgery. A total of 317 (26.4%) patients had at least one complication of which 123 (38%) were considered as severe (DINDO III/IV). New surgery was necessary in 69 (5.7%) patients and secondary stoma in 23 (1.9%). Three deaths were observed (0.25%). The rates of overall complications in patients not exposed to biologics, exposed to anti-TNFs, ustekinumab or vedolizumab were respectively 26.1%, 25.1%, 34.7% and 29.8%. The risks of intra-abdominal infectious complications in these four groups were respectively 13.5%, 11.1%, 13.3% and 8.8%. In multivariate analysis, age [OR, 1.02 (1.01-1.04); p=0.004], disease activity [OR, 8.36 (1.79 – 149); p=0.037], the presence of an abscess [OR, 2.01 (1.25-3.20); p=0.004] and initial stoma [OR, 1.70 (1.10 –2.61); p=0.016] were significantly associated with intra-abdominal infectious complications. Conversely, preoperative enteral nutrition [OR, 0.12 (0.01 -0.59); p=0.040] was associated with a reduction in this risk. Exposure to anti-TNFs [OR, 0.80 (0.51-1.24); p=0.31], ustekinumab [OR, 1.17 (0.39-3.51); p=0.78] and vedolizumab [OR, 1.28 (0.32-5.17); p=0.72] within the 3 months before surgery were not associated with the risk of intra-abdominal infectious complications. Similar results were observed in patients exposed to these treatments in the month before surgery. Conclusion In this large cohort, a quarter of patients operated on for CD presented an early postoperative complication and 10% a severe complication. Preoperative exposure to anti-TNFs, vedolizumab or ustekinumab was not associated with an increased risk of early postoperative complications. Preoperative enteral nutrition was associated with a reduced risk of intra-abdominal infectious complication

P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study

Meeting abstract du "19th Congress of ECCO", Stockholm, Suède, 21-24 février, 2024International audienceBackground Risankizumab is approved for moderate to severe Crohn’s disease (CD). The GETAID recently reported the real-world effectiveness of risankizumab as induction therapy for refractory CD. The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with CD. Methods From May 2021 to August 2023, all consecutive CD patients treated with risankizumab in 25 GETAID centers have been retrospectively included. Only patients who received risankizumab 600 mg IV at week 0,4 and 8 as induction and SC 360 mg every 8 weeks as maintenance treatment were included. The primary outcome measure was steroid-free clinical remission (Harvey Bradshaw Index (HBI) < 5) at week 52. Secondary outcomes included clinical response (≥ 3-point decrease of HB score and/or (HB) score < 5), endoscopic (no ulcers) and/or radiologic remission (normal intestinal ultra-sound or MRI), need for CD-related surgery, and adverse events. Results All patients had received at least three biologics and 108 (62%) had previous intestinal resection. Of the 174 patients included, 172 (99%), 162 (93%), and 167 (96%) had been previously exposed to anti-TNF, vedolizumab, and ustekinumab, respectively. Respectively 66 (38%) and 24 (14%) patients were on corticosteroids and immunosuppressants at risankizumab initiation. Median follow-up was 13.7 (10.0-18.1) months. The rates of steroid-free clinical remission and clinical remission at 52 weeks were 46% (60/131) and 50% (65/131), respectively. Absence/mild abdominal pain with normal stool frequency was observed in 48% (54/112) of patients at week 52. Among the 79 (45%) patients who had an endoscopic (n=67) and/or radiological (MRI, n=56 and IUS, n=15) evaluation during follow-up, response and remission were observed in 27 (34%) and 17 (22%) patients, respectively. Risankizumab persistence rates were 94%, 89%, and 79% at weeks 12, 26, and 52, respectively. At the end of follow-up, 45 (45/174, 26%) patients had discontinued risankizumab (loss of response, 42%; primary failure, 37%; intolerance, 13%). Thirty-six patients (36/174, 20.9%) were hospitalized and 22 (22/174, 12.6%) required intestinal resection. No factors were associated with steroid-free clinical remission at week 52. Twenty-five (14%) patients had an adverse event and 26 (15%) serious adverse events (CD flare, n=17). One death (myocardial infarction) and one cancer (papillary thyroid carcinoma) were observed. Conclusion This is the first real-life study to report long-term outcomes in patients with refractory CD treated with risankizumab. Half of the patients achieved steroid-free clinical remission after one year, and the safety profile was consistent with the literature